Genprex to Participate at BIO Europe Spring 2026

Core Insights - Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, and will participate in BIO Europe Spring 2026 in Lisbon, Portugal [1] - The company aims to provide an overview of its gene therapies during the conference, with executives available for one-on-one meetings [1] - Genprex's lead product candidate, Reqorsa® Gene Therapy, is under evaluation in clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), both of which have received Fast Track Designation from the FDA [1] Company Overview - Genprex, Inc. specializes in gene therapy, targeting large patient populations with limited treatment options for cancer and diabetes [1] - The company's oncology program utilizes the Oncoprex® Delivery System, which employs lipid-based nanoparticles to deliver gene-expressing plasmids intravenously [1] - The diabetes gene therapy approach involves an AAV vector to deliver Pdx1 and MafA genes to the pancreas, aiming to transform alpha cells into functional beta-like cells [1] Clinical Development - Reqorsa® Gene Therapy is being evaluated in two clinical trials for NSCLC and SCLC, with the SCLC program receiving FDA Orphan Drug Designation [1] - The diabetes therapy GPX-002 is designed to rejuvenate and replenish exhausted beta cells in Type 2 diabetes and transform alpha cells in Type 1 diabetes [1] Event Participation - BIO Europe Spring 2026 is expected to attract over 3,700 executives from biotech, pharma, and finance sectors, facilitating more than 20,000 one-on-one meetings [1] - Genprex executives, including the President and CEO, will be present to engage with industry leaders and investors [1]